Gilead To Seek Approval For Hepatitis C Drug Combo; Cures Up To 99 Percent Of Patients

By | Wed, 12/18/2013 - 22:22

Gilead's combo of ledipasvir and Sovaldi could revolutionize Hepatitis C treatment, as initial results show that the drugs cured over 90 percent of cases in as little as eight weeks.


FDA Approves Sovaldi For Hepatitis C

By | Sat, 12/07/2013 - 13:45

Gilead Sciences' Sovaldi (sofosbuvir) received approval from the U.S. Food and Drug Administration for the treatment of hepatitis C.

David Matthew Kwiatkowski

Hospital Tech Who Infected Patients With Hepatitis C Faces Up To 40 Years In Federal Prison

By | Mon, 12/02/2013 - 14:48

David Kwiatkowski, a traveling hospital technician who infected at least 32 people with hepatitis C using syringes tainted with his own infected blood, will receive his sentence on Monday.


Gilead Combination Pill Cures 95% Hepatitis C Patients

By | Tue, 11/05/2013 - 20:35

A double-drug combination pill was able to cure 95 percent of hepatitis C patients, regardless of how they responded to currently available treatments.

hepatitis injection

Hepatitis C: Combo Of Merck Drugs May Provide Cure Without Brutal Side Effects

By | Sat, 11/02/2013 - 14:43

A combination of two oral hepatitis C drugs manufactured by Merck lead to high cure rates and less side effects in a clinical trial, prompting some patients to wait for it to come to market.


Pregnancy Could Help Hepatitis C Develop Into Hardier Strain

By | Tue, 10/29/2013 - 20:32

In one mother, the processes that occurred during pregnancy combined with the natural viral processes of hepatitis C to help create a strain that was able to replicate faster.

stomach endoscopy

Las Vegas Doctor, Dipak Desai, Sentenced To Life In Prison After Hepatitis C Scandal

By | Fri, 10/25/2013 - 18:48

The doctor who infected nine patients with Hepatitis C is guilty of 27 charges and has received a life sentence.

hepatitis c

Gilead's Hepatitis C Drug Gets Positive Review From FDA

By | Wed, 10/23/2013 - 16:31

A new wave of hepatitis C drugs could improve the cure rate for the scores of people who don't respond well to current treatments.


Hepatitis C Cure? Sofosbuvir Plus Ribavirin Show Promise In NIH Trial

By | Tue, 08/27/2013 - 14:51

The hepatitis C virus was stopped in hard-to-treat patients with the experimental combination of sofosbuvir and ribavirin.

David Matthew Kwiatkowski

Hospital Tech Admits To Using Own Blood To Infect People With Hepatitis C

By | Tue, 08/13/2013 - 09:55

David Kwiatkowski, a traveling hospital technician, is set to plead guilty Tuesday for infecting at least 32 people with hepatitis C using syringes tainted with his own infected blood.

Hepatitis C Testing

Baby Boomers: Get Tested For Hepatitis C, Says US Advisory Panel

By | Tue, 06/25/2013 - 13:38

The US Preventive Services Task Force has issued guidelines encouraging baby boomers to be tested for hepatitis C.

Hepatitis C

First Hepatitis C Genotyping Test Approved By FDA, Heralding Personalized Treatment Before Curing Drug Introductions

By | Thu, 06/20/2013 - 14:25

The newly FDA-approved hepatitis C genotyping test comes months before the FDA is set to announce approvals of new drugs for certain genotypes of the virus.

Hepatitis C

FDA Grants Priority Review To Oral Hepatitis C Drug Sofosbuvir, Approval Decision Set For December

By | Mon, 06/10/2013 - 10:05

Gilead's drug will be one of the first to hit the market in a new generation of targeted hepatitis C treatments with high cure rates.

Hepatitis C treatment gets FDA priority review

Simeprevir Given Priority Review Status By FDA For Hepatitis C Treatment

By | Mon, 05/13/2013 - 10:21

With stunning results in Phase III clinical trials, the hepatitis C drug is now on a fast track for FDA approval.

Hepatitis-induced jaundice

Over 50% Hepatitis Cases Don't Follow Through With Testing, At Risk For Liver Disease, Says CDC

By | Tue, 05/07/2013 - 14:19

CDC finds half of Americans with Hepatitis C, mostly baby boomers, don’t follow up after initial screening and might require medical treatment.